Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants
Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradication in murine models. These observations suggest tha...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 1997-05, Vol.19 (9), p.867-873 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 873 |
|---|---|
| container_issue | 9 |
| container_start_page | 867 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 19 |
| creator | LINDGREN, C. G THOMPSON, J. A ROBINSON, N KEELER, T GOLD, P. J FEFER, A |
| description | Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradication in murine models. These observations suggest that IL-12 might have a role as treatment for minimal residual disease following transplantation. To determine whether PBL from recipients of autologous (autoSCT) and allogeneic (alloSCT) bone marrow or peripheral blood stem cell transplants respond to IL-12 with generation of LAK activity, PBL were incubated with IL-12 for 5 days, then tested in a 51Cr release assay for lysis of Daudi. PBL from 17 normal 'control' individuals were similarly tested and lysis was observed in only 3/17 (mean 16.9% of the three). By contrast, PBL from 10/12 patients obtained a median of 30 days after autoSCT, exhibited significant IL-12-induced LAK activity (mean lysis, 35.3%, P < 0.005 vs controls). PBL from 18 of 20 patients tested a median of 44 days after alloSCT also exhibited significant LAK activity (mean lysis, 30.0%, P < 0.005 vs controls). In autoSCT recipients, IL-12 and IL-2 at high concentrations (1000 U/ml each) were additive for induction of LAK activity, whereas low, suboptimal concentration of IL-12 (250 U/ml) and IL-2 (1 U/ml) were synergistic in 3/5 experiments. The percentage of PBL expressing IL-12 receptor beta 1 chain (IL-12r beta 1) was higher in stem cell recipients than in normal individuals, P < 0.05. Moreover, a higher percentage of IL-12r beta 1-positive PBL was associated with greater IL-12-induced LAK activity in transplant recipients. These studies demonstrate that PBL obtained early after stem cell transplantation have a higher percentage of cells expressing IL-12r beta 1 and respond to IL-12 with significantly greater LAK cytotoxicity than PBL from normal controls. These results suggest that IL-12 is a potentially attractive candidate for study as consolidative immunotherapy after stem cell transplantation. |
| doi_str_mv | 10.1038/sj.bmt.1700774 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79026785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16229348</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-975e025523794b3268273fba118f5211d1777b94f9152205bcc6944f68e0b1943</originalsourceid><addsrcrecordid>eNqFkc1rFTEUxUNR6mt1604IWNzNM98fSynWFgpudB0ymUzNcyYZk4ww-M-b0qELN65COL97uOceAN5idMSIqo_ldOznesQSISnZGThgJkXHqeAvwAERoTpKhX4FLko5IYQZQ_wcnGvMBeH6AP7cxerz5NefIXaYwBCH1fkBuq2maavBQetq-B3q1iQ4bfPyIzXNFzjmNMPsXViCj7XANEK7tqH0kNYCbRygndrHR99MSvUzdH6aYM02lmWybeQ1eDnaqfg3-3sJvt98_nZ9291__XJ3_em-cwyr2mnJPSKcEyo162mLRCQde4uxGjnBeMBSyl6zsYUiBPHeOaEZG4XyqMea0Uvw4cl3yenX6ks1cyiPy9jo265G6nYnqfh_QSwI0ZSpBr7_BzylNccWwhDBCOZUUdSo4xPlciol-9EsOcw2bwYj81ieKSfTyjN7eW3g3W679rMfnvG9raZf7botzk5jO6UL5RkjQnDVbP4C-xGjCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642153830</pqid></control><display><type>article</type><title>Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>LINDGREN, C. G ; THOMPSON, J. A ; ROBINSON, N ; KEELER, T ; GOLD, P. J ; FEFER, A</creator><creatorcontrib>LINDGREN, C. G ; THOMPSON, J. A ; ROBINSON, N ; KEELER, T ; GOLD, P. J ; FEFER, A</creatorcontrib><description>Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradication in murine models. These observations suggest that IL-12 might have a role as treatment for minimal residual disease following transplantation. To determine whether PBL from recipients of autologous (autoSCT) and allogeneic (alloSCT) bone marrow or peripheral blood stem cell transplants respond to IL-12 with generation of LAK activity, PBL were incubated with IL-12 for 5 days, then tested in a 51Cr release assay for lysis of Daudi. PBL from 17 normal 'control' individuals were similarly tested and lysis was observed in only 3/17 (mean 16.9% of the three). By contrast, PBL from 10/12 patients obtained a median of 30 days after autoSCT, exhibited significant IL-12-induced LAK activity (mean lysis, 35.3%, P < 0.005 vs controls). PBL from 18 of 20 patients tested a median of 44 days after alloSCT also exhibited significant LAK activity (mean lysis, 30.0%, P < 0.005 vs controls). In autoSCT recipients, IL-12 and IL-2 at high concentrations (1000 U/ml each) were additive for induction of LAK activity, whereas low, suboptimal concentration of IL-12 (250 U/ml) and IL-2 (1 U/ml) were synergistic in 3/5 experiments. The percentage of PBL expressing IL-12 receptor beta 1 chain (IL-12r beta 1) was higher in stem cell recipients than in normal individuals, P < 0.05. Moreover, a higher percentage of IL-12r beta 1-positive PBL was associated with greater IL-12-induced LAK activity in transplant recipients. These studies demonstrate that PBL obtained early after stem cell transplantation have a higher percentage of cells expressing IL-12r beta 1 and respond to IL-12 with significantly greater LAK cytotoxicity than PBL from normal controls. These results suggest that IL-12 is a potentially attractive candidate for study as consolidative immunotherapy after stem cell transplantation.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1700774</identifier><identifier>PMID: 9156259</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Animal models ; Antineoplastic agents ; Autografts ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Cells, Cultured ; Chromium radioisotopes ; Cytokines ; Cytolytic activity ; Cytotoxicity ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Immunotherapy ; Interleukin 12 ; Interleukin 2 ; Interleukin-12 - metabolism ; Interleukin-12 - pharmacology ; Interleukins ; Killer Cells, Lymphokine-Activated - drug effects ; Leukocytes, Mononuclear - drug effects ; Lymphocytes ; Lymphocytes T ; Lysis ; Medical sciences ; Minimal residual disease ; Patients ; Peripheral blood ; Pharmacology. Drug treatments ; Receptors, Interleukin - metabolism ; Receptors, Interleukin-12 ; Stem cell transplantation ; Stem cells ; Toxicity ; Transplantation ; Transplantation, Autologous ; Transplantation, Homologous ; Transplants ; Tumors</subject><ispartof>Bone marrow transplantation (Basingstoke), 1997-05, Vol.19 (9), p.867-873</ispartof><rights>1997 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1997.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-975e025523794b3268273fba118f5211d1777b94f9152205bcc6944f68e0b1943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2665874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9156259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LINDGREN, C. G</creatorcontrib><creatorcontrib>THOMPSON, J. A</creatorcontrib><creatorcontrib>ROBINSON, N</creatorcontrib><creatorcontrib>KEELER, T</creatorcontrib><creatorcontrib>GOLD, P. J</creatorcontrib><creatorcontrib>FEFER, A</creatorcontrib><title>Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradication in murine models. These observations suggest that IL-12 might have a role as treatment for minimal residual disease following transplantation. To determine whether PBL from recipients of autologous (autoSCT) and allogeneic (alloSCT) bone marrow or peripheral blood stem cell transplants respond to IL-12 with generation of LAK activity, PBL were incubated with IL-12 for 5 days, then tested in a 51Cr release assay for lysis of Daudi. PBL from 17 normal 'control' individuals were similarly tested and lysis was observed in only 3/17 (mean 16.9% of the three). By contrast, PBL from 10/12 patients obtained a median of 30 days after autoSCT, exhibited significant IL-12-induced LAK activity (mean lysis, 35.3%, P < 0.005 vs controls). PBL from 18 of 20 patients tested a median of 44 days after alloSCT also exhibited significant LAK activity (mean lysis, 30.0%, P < 0.005 vs controls). In autoSCT recipients, IL-12 and IL-2 at high concentrations (1000 U/ml each) were additive for induction of LAK activity, whereas low, suboptimal concentration of IL-12 (250 U/ml) and IL-2 (1 U/ml) were synergistic in 3/5 experiments. The percentage of PBL expressing IL-12 receptor beta 1 chain (IL-12r beta 1) was higher in stem cell recipients than in normal individuals, P < 0.05. Moreover, a higher percentage of IL-12r beta 1-positive PBL was associated with greater IL-12-induced LAK activity in transplant recipients. These studies demonstrate that PBL obtained early after stem cell transplantation have a higher percentage of cells expressing IL-12r beta 1 and respond to IL-12 with significantly greater LAK cytotoxicity than PBL from normal controls. These results suggest that IL-12 is a potentially attractive candidate for study as consolidative immunotherapy after stem cell transplantation.</description><subject>Animal models</subject><subject>Antineoplastic agents</subject><subject>Autografts</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Cells, Cultured</subject><subject>Chromium radioisotopes</subject><subject>Cytokines</subject><subject>Cytolytic activity</subject><subject>Cytotoxicity</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interleukin 12</subject><subject>Interleukin 2</subject><subject>Interleukin-12 - metabolism</subject><subject>Interleukin-12 - pharmacology</subject><subject>Interleukins</subject><subject>Killer Cells, Lymphokine-Activated - drug effects</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lysis</subject><subject>Medical sciences</subject><subject>Minimal residual disease</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Interleukin - metabolism</subject><subject>Receptors, Interleukin-12</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Toxicity</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Transplantation, Homologous</subject><subject>Transplants</subject><subject>Tumors</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1rFTEUxUNR6mt1604IWNzNM98fSynWFgpudB0ymUzNcyYZk4ww-M-b0qELN65COL97uOceAN5idMSIqo_ldOznesQSISnZGThgJkXHqeAvwAERoTpKhX4FLko5IYQZQ_wcnGvMBeH6AP7cxerz5NefIXaYwBCH1fkBuq2maavBQetq-B3q1iQ4bfPyIzXNFzjmNMPsXViCj7XANEK7tqH0kNYCbRygndrHR99MSvUzdH6aYM02lmWybeQ1eDnaqfg3-3sJvt98_nZ9291__XJ3_em-cwyr2mnJPSKcEyo162mLRCQde4uxGjnBeMBSyl6zsYUiBPHeOaEZG4XyqMea0Uvw4cl3yenX6ks1cyiPy9jo265G6nYnqfh_QSwI0ZSpBr7_BzylNccWwhDBCOZUUdSo4xPlciol-9EsOcw2bwYj81ieKSfTyjN7eW3g3W679rMfnvG9raZf7botzk5jO6UL5RkjQnDVbP4C-xGjCA</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>LINDGREN, C. G</creator><creator>THOMPSON, J. A</creator><creator>ROBINSON, N</creator><creator>KEELER, T</creator><creator>GOLD, P. J</creator><creator>FEFER, A</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants</title><author>LINDGREN, C. G ; THOMPSON, J. A ; ROBINSON, N ; KEELER, T ; GOLD, P. J ; FEFER, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-975e025523794b3268273fba118f5211d1777b94f9152205bcc6944f68e0b1943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animal models</topic><topic>Antineoplastic agents</topic><topic>Autografts</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Cells, Cultured</topic><topic>Chromium radioisotopes</topic><topic>Cytokines</topic><topic>Cytolytic activity</topic><topic>Cytotoxicity</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interleukin 12</topic><topic>Interleukin 2</topic><topic>Interleukin-12 - metabolism</topic><topic>Interleukin-12 - pharmacology</topic><topic>Interleukins</topic><topic>Killer Cells, Lymphokine-Activated - drug effects</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lysis</topic><topic>Medical sciences</topic><topic>Minimal residual disease</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Interleukin - metabolism</topic><topic>Receptors, Interleukin-12</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Toxicity</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Transplantation, Homologous</topic><topic>Transplants</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LINDGREN, C. G</creatorcontrib><creatorcontrib>THOMPSON, J. A</creatorcontrib><creatorcontrib>ROBINSON, N</creatorcontrib><creatorcontrib>KEELER, T</creatorcontrib><creatorcontrib>GOLD, P. J</creatorcontrib><creatorcontrib>FEFER, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LINDGREN, C. G</au><au>THOMPSON, J. A</au><au>ROBINSON, N</au><au>KEELER, T</au><au>GOLD, P. J</au><au>FEFER, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>19</volume><issue>9</issue><spage>867</spage><epage>873</epage><pages>867-873</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradication in murine models. These observations suggest that IL-12 might have a role as treatment for minimal residual disease following transplantation. To determine whether PBL from recipients of autologous (autoSCT) and allogeneic (alloSCT) bone marrow or peripheral blood stem cell transplants respond to IL-12 with generation of LAK activity, PBL were incubated with IL-12 for 5 days, then tested in a 51Cr release assay for lysis of Daudi. PBL from 17 normal 'control' individuals were similarly tested and lysis was observed in only 3/17 (mean 16.9% of the three). By contrast, PBL from 10/12 patients obtained a median of 30 days after autoSCT, exhibited significant IL-12-induced LAK activity (mean lysis, 35.3%, P < 0.005 vs controls). PBL from 18 of 20 patients tested a median of 44 days after alloSCT also exhibited significant LAK activity (mean lysis, 30.0%, P < 0.005 vs controls). In autoSCT recipients, IL-12 and IL-2 at high concentrations (1000 U/ml each) were additive for induction of LAK activity, whereas low, suboptimal concentration of IL-12 (250 U/ml) and IL-2 (1 U/ml) were synergistic in 3/5 experiments. The percentage of PBL expressing IL-12 receptor beta 1 chain (IL-12r beta 1) was higher in stem cell recipients than in normal individuals, P < 0.05. Moreover, a higher percentage of IL-12r beta 1-positive PBL was associated with greater IL-12-induced LAK activity in transplant recipients. These studies demonstrate that PBL obtained early after stem cell transplantation have a higher percentage of cells expressing IL-12r beta 1 and respond to IL-12 with significantly greater LAK cytotoxicity than PBL from normal controls. These results suggest that IL-12 is a potentially attractive candidate for study as consolidative immunotherapy after stem cell transplantation.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>9156259</pmid><doi>10.1038/sj.bmt.1700774</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 1997-05, Vol.19 (9), p.867-873 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79026785 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animal models Antineoplastic agents Autografts Biological and medical sciences Bone marrow Bone marrow transplantation Cells, Cultured Chromium radioisotopes Cytokines Cytolytic activity Cytotoxicity Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Immunotherapy Interleukin 12 Interleukin 2 Interleukin-12 - metabolism Interleukin-12 - pharmacology Interleukins Killer Cells, Lymphokine-Activated - drug effects Leukocytes, Mononuclear - drug effects Lymphocytes Lymphocytes T Lysis Medical sciences Minimal residual disease Patients Peripheral blood Pharmacology. Drug treatments Receptors, Interleukin - metabolism Receptors, Interleukin-12 Stem cell transplantation Stem cells Toxicity Transplantation Transplantation, Autologous Transplantation, Homologous Transplants Tumors |
| title | Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A20%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-12%20induced%20cytolytic%20activity%20in%20lymphocytes%20from%20recipients%20of%20autologous%20and%20allogeneic%20stem%20cell%20transplants&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=LINDGREN,%20C.%20G&rft.date=1997-05-01&rft.volume=19&rft.issue=9&rft.spage=867&rft.epage=873&rft.pages=867-873&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1700774&rft_dat=%3Cproquest_cross%3E16229348%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642153830&rft_id=info:pmid/9156259&rfr_iscdi=true |